Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial - PubMed
3 days ago
- #HIV-1
- #gut microbiota
- #antiretroviral therapy
- Dolutegravir-based therapy restores gut microbiota more effectively than darunavir/ritonavir in late-stage HIV-1 patients.
- The study was an open-label, randomized clinical trial involving 88 antiretroviral-naïve individuals with advanced HIV-1 infection.
- Participants were randomized to receive either dolutegravir or ritonavir-boosted darunavir and followed for 2 years.
- Both groups showed similar HIV-1 suppression rates and CD4+ T cell recovery.
- Dolutegravir treatment led to increased gut microbial richness and diversity, reduced inflammation, and lower immune activation.
- After two years, dolutegravir-treated patients had gut microbiota profiles more resembling those of HIV-negative individuals.
- The findings highlight the importance of specific antiretroviral regimens in restoring gut microbiota and improving long-term health in HIV patients.